Cargando…

Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial

BACKGROUND: Nutrition in the intensive care unit is vital for patient care; however, immunomodulatory diets rich in PUFAs like γ-linolenic acid (GLA), EPA, and DHA remain controversial for patients with acute respiratory distress syndrome. We postulate that genetic variants impacting PUFA metabolism...

Descripción completa

Detalles Bibliográficos
Autores principales: Dosso, Beverly, Waits, Charlotte Mae K, Simms, Kelli N, Sergeant, Susan, Files, D Clark, Howard, Timothy D, Langefeld, Carl D, Chilton, Floyd H, Rahbar, Elaheh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524639/
https://www.ncbi.nlm.nih.gov/pubmed/33024925
http://dx.doi.org/10.1093/cdn/nzaa147
_version_ 1783588581714952192
author Dosso, Beverly
Waits, Charlotte Mae K
Simms, Kelli N
Sergeant, Susan
Files, D Clark
Howard, Timothy D
Langefeld, Carl D
Chilton, Floyd H
Rahbar, Elaheh
author_facet Dosso, Beverly
Waits, Charlotte Mae K
Simms, Kelli N
Sergeant, Susan
Files, D Clark
Howard, Timothy D
Langefeld, Carl D
Chilton, Floyd H
Rahbar, Elaheh
author_sort Dosso, Beverly
collection PubMed
description BACKGROUND: Nutrition in the intensive care unit is vital for patient care; however, immunomodulatory diets rich in PUFAs like γ-linolenic acid (GLA), EPA, and DHA remain controversial for patients with acute respiratory distress syndrome. We postulate that genetic variants impacting PUFA metabolism contribute to mixed responses to PUFA-rich diets. OBJECTIVES: In this study, we aimed to test the effects of single nucleotide polymorphism (SNP) rs174537 on differential responses to PUFA-rich diets. METHODS: We performed a secondary analysis of the OMEGA trial (NCT00609180) where 129 subjects received placebo control diets and 143 received omega-oil. DNA was extracted from buffy coats and used to genotype rs174537; plasma was used to quantitate PUFAs. We tested for SNP–diet interactions on PUFA concentrations, inflammatory biomarkers, and patient outcomes. RESULTS: We observed that all individuals receiving omega-oil displayed significantly higher concentrations of GLA, EPA, and DHA (all P < 0.0001), but they did not vary by genotype at rs174537. Statistically significant SNP–diet interactions were observed on circulating DHA concentrations in African Americans. Specifically, African American T-allele carriers on placebo illustrated elevated DHA concentrations. Additionally, all individuals receiving omega-oil had higher concentrations of EPA-derived urinary F3-isoprostane (Caucasians: P = 0.0011; African Americans: P = 0.0002). Despite these findings, we did not detect any significant SNP–diet interactions on pulmonary functional metrics, clinical outcomes, and mortality. CONCLUSIONS: This study highlights the importance of genetic and racial contributions to PUFA metabolism and inflammation. In particular, rs174537 had a significant impact on circulating DHA and urinary isoprostane concentrations. Given our relatively small sample size, further investigations in larger multiethnic cohorts are needed to evaluate the impact of rs174537 on fatty acid metabolism and downstream inflammation.
format Online
Article
Text
id pubmed-7524639
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-75246392020-10-05 Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial Dosso, Beverly Waits, Charlotte Mae K Simms, Kelli N Sergeant, Susan Files, D Clark Howard, Timothy D Langefeld, Carl D Chilton, Floyd H Rahbar, Elaheh Curr Dev Nutr Original Research BACKGROUND: Nutrition in the intensive care unit is vital for patient care; however, immunomodulatory diets rich in PUFAs like γ-linolenic acid (GLA), EPA, and DHA remain controversial for patients with acute respiratory distress syndrome. We postulate that genetic variants impacting PUFA metabolism contribute to mixed responses to PUFA-rich diets. OBJECTIVES: In this study, we aimed to test the effects of single nucleotide polymorphism (SNP) rs174537 on differential responses to PUFA-rich diets. METHODS: We performed a secondary analysis of the OMEGA trial (NCT00609180) where 129 subjects received placebo control diets and 143 received omega-oil. DNA was extracted from buffy coats and used to genotype rs174537; plasma was used to quantitate PUFAs. We tested for SNP–diet interactions on PUFA concentrations, inflammatory biomarkers, and patient outcomes. RESULTS: We observed that all individuals receiving omega-oil displayed significantly higher concentrations of GLA, EPA, and DHA (all P < 0.0001), but they did not vary by genotype at rs174537. Statistically significant SNP–diet interactions were observed on circulating DHA concentrations in African Americans. Specifically, African American T-allele carriers on placebo illustrated elevated DHA concentrations. Additionally, all individuals receiving omega-oil had higher concentrations of EPA-derived urinary F3-isoprostane (Caucasians: P = 0.0011; African Americans: P = 0.0002). Despite these findings, we did not detect any significant SNP–diet interactions on pulmonary functional metrics, clinical outcomes, and mortality. CONCLUSIONS: This study highlights the importance of genetic and racial contributions to PUFA metabolism and inflammation. In particular, rs174537 had a significant impact on circulating DHA and urinary isoprostane concentrations. Given our relatively small sample size, further investigations in larger multiethnic cohorts are needed to evaluate the impact of rs174537 on fatty acid metabolism and downstream inflammation. Oxford University Press 2020-09-14 /pmc/articles/PMC7524639/ /pubmed/33024925 http://dx.doi.org/10.1093/cdn/nzaa147 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of American Society for Nutrition. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Research
Dosso, Beverly
Waits, Charlotte Mae K
Simms, Kelli N
Sergeant, Susan
Files, D Clark
Howard, Timothy D
Langefeld, Carl D
Chilton, Floyd H
Rahbar, Elaheh
Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial
title Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial
title_full Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial
title_fullStr Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial
title_full_unstemmed Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial
title_short Impact of rs174537 on Critically Ill Patients with Acute Lung Injury: A Secondary Analysis of the OMEGA Randomized Clinical Trial
title_sort impact of rs174537 on critically ill patients with acute lung injury: a secondary analysis of the omega randomized clinical trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7524639/
https://www.ncbi.nlm.nih.gov/pubmed/33024925
http://dx.doi.org/10.1093/cdn/nzaa147
work_keys_str_mv AT dossobeverly impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT waitscharlottemaek impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT simmskellin impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT sergeantsusan impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT filesdclark impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT howardtimothyd impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT langefeldcarld impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT chiltonfloydh impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial
AT rahbarelaheh impactofrs174537oncriticallyillpatientswithacutelunginjuryasecondaryanalysisoftheomegarandomizedclinicaltrial